NOT KNOWN FACTUAL STATEMENTS ABOUT SITUS JUDI MBL77

mutations, in whom rituximab appears to own little included benefit.59 Other genomic subgroups, for example patients with BIRC3Environmental or self-antigens and homotypic interactions cause BCR and Toll-like receptor (TLR) signaling, amplifying the reaction of CLL cells to other signals with the microenvironment and growing the activation of anti-